Nu-Med Plus (NUMD) Cash from Operations Growth (1y) (2013 - 2025)
Nu-Med Plus (NUMD) Cash from Operations Growth (1y) (2013 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | -7.20% |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 132.40% |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 6.69% |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | -35.67% |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | -84.38% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 122.43% |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 185.96% |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 16.00% |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 28.60% |
| 10 | Nu-Med Plus | - | - | - | -2,001.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2,001.56% |
| Dec 31, 2024 | 61.05% |
| Jun 30, 2024 | 89.97% |
| Mar 31, 2024 | 97.77% |
| Dec 31, 2023 | 82.47% |
| Sep 30, 2023 | -3,104.62% |
| Jun 30, 2023 | -809.42% |
| Mar 31, 2023 | -66.14% |
| Dec 31, 2022 | -21.17% |
| Sep 30, 2022 | 101.53% |
| Jun 30, 2022 | 96.18% |
| Mar 31, 2022 | 84.68% |
| Dec 31, 2021 | 71.70% |
| Sep 30, 2021 | 59.42% |
| Jun 30, 2021 | 54.91% |
| Mar 31, 2021 | 16.75% |
| Dec 31, 2020 | 42.85% |
| Sep 30, 2020 | -33.87% |
| Jun 30, 2020 | -22.25% |
| Mar 31, 2020 | 61.41% |